Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

Ninth Amendment to Credit Agreement; Extended Maturity Date

As previously reported, CareView Communications, Inc. (and together with its subsidiaries, as applicable, the "Company"), CareView Communications, Inc., a Texas corporation and a wholly owned subsidiary of the Company (the "Borrower"), and PDL Investment Holdings, LLC (as assignee of PDL BioPharma, Inc.), in its capacity as administrative agent and lender (the "Lender") entered into that certain Credit Agreement as of June 26, 2015, which was subsequently amended by the First Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment, the Fifth Amendment, the Sixth Amendment, the Seventh Amendment and the Eight Amendment as of October 7, 2015, February 23, 2018, July 13, 2018, April 9, 2019, May 15, 2019, February 6, 2020, May 31, 2023, and September 30, 2023 respectively (collectively, the "Credit Agreement"). Any capitalized terms not defined herein shall have the definitions ascribed to them in the Credit Agreement.

On December 11, 2024 (the "Effective Date"), the Company, the Borrower, the Lender, Steven G. Johnson, President and Chief Executive Officer of the Company, and Dr. James R. Higgins, a director of the Company, entered into a Ninth Amendment to Credit Agreement (the "Ninth Credit Agreement Amendment"), pursuant to which the parties agreed to amend the Credit Agreement to (i) provide that the Maturity Date shall be extended to March 31, 2025.

The foregoing descriptions of the Ninth Amendment to Credit Agreement are qualified, in their entirety, by reference to such amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in response to this Item 1.01.